Victoza now only GLP-1 in EU with a label to include prevention of cardiovascular events

28 July 2017

The European Commission has approved an update to the Victoza (liraglutide) label in the European Union that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events as integral parts of type 2 diabetes treatment.

This makes Danish diabetes care giant Novo Nordisk’s (NOV: N) Victoza the only GLP-1 that is proven to prevent CV events in people with type 2 diabetes and high CV risk.

The drug is one of the company’s best sellers and Victoza sales last year rose 12% to 20 billion Danish kroner ($3.13 billion). However, it is starting to come under pressure from Eli Lilly & Co’s (NYSE: ELY) product Trulicity (dulaglutide), a weekly injection. The new indication should give Victoza a competitive edge.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK